MedTrace Logo

Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke

NCT06386289 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-09-02

No results posted yet for this study

Summary

The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease

Conditions

  • Acute Ischemic Stroke

Interventions

DEVICE

Cereglide 92

Aspiration of cerebral large vessels occlusions

Sponsors & Collaborators

  • Cerenovus, Part of DePuy Synthes Products, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Froehler, MD, PhD · Vanderbilt University Medical Center

  • Brian Jankowitz, MD · JFK University Medical Center

  • Ansaar Rai, MD · West Virginia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2026-02-28
Completion
2026-06-30
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06386289 on ClinicalTrials.gov